TrialBritish journal of cancer2011

A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma.

S O'Day et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.